Funding momentum Sylentis has recently secured substantial grants and licensing income, highlighting available funding channels and potential collaboration opportunities with entities interested in ophthalmology-focused gene silencing therapies.

Therapeutic focus With a strong pipeline in glaucoma and dry eye disease and ongoing Phase III activities for dry eye treatment, there are clear opportunities to discuss companion diagnostics, regulatory strategy support, and access to ophthalmic trial sites.

Strategic backing As a wholly owned subsidiary of PharmaMar, Sylentis benefits from corporate stability, potential cross-pollination for oligonucleotide manufacturing, and access to PharmaMar’s broader oncology and biotech network for strategic partnerships.

Manufacturing capacity Recent expansion of GMP-compliant oligonucleotide manufacturing facilities in Madrid enhances supply reliability and potential for scale-up collaborations, including contract development and manufacturing services (CDMO) for RNA-based therapeutics.

Executive leadership Recent leadership appointment signals a potential shift in strategy and commercial execution; a proactive engagement with the CEO and executive team could align on market access, partnerships, and clinical trial strategies in ophthalmology.